Abstract
Chronic-phase chronic myeloid leukemia (CML-CP) treatment has significantly improved in recent years. The generational development of small molecule tyrosine kinase inhibitors (TKIs) such as Imatinib and Dasatinib, has revolutionized the treatment of CML. Their mechanisms and efficacy have been clear, but there is no literature review to summarize or comprehensively compare their efficacy and safety. Studies have revealed that second-generation TKI therapy yields noticeably greater response rates than imatinib and there is no marked difference in treatment-related adverse events between the two therapies. According to this direction, A double-therapies analysis was performed to assess the efficacy and tolerability of various front-line treatments for individuals with CML-CP. Both direct and indirect comparisons between the various treatment choices were taken into account in this general analysis. The author took Imatinib and Dasatinib as the main comparison objects and provide a comprehensive assessment of the two available therapies for CML-CP. By comparing the efficacy outcomes and adverse effects (AEs), the study was aimed to identify the treatment options that are both highly effective and well-tolerated for patients in general.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
